Clinical trials: Diabetic Oculopathy
Diabetic Retinopathy, Retinal Vein Occlusion
Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph
Blindness can be caused by many ocular diseases, such as diabetic retinopathy, retinal vein occlusion, age-related macular degeneration, pathologic myopia and glaucoma.
- Conditions
- Diabetic Retinopathy, Retinal Vein Occlusion, Retinal Artery Occlusion, Central Serous Chorioretinopathy
- Trial name
- NCT04723160
- Testing
- Software assisted imaging diagnosis
- Where
- 5 sites in China
- Volunteers
- 748 people, healthy volunteers welcome
- Sponsor
- Visionary Intelligence Ltd.
Retinal Disease
Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice
The study aims to collect data on the safety and use of intravitreal aflibercept injections into the eye for the treatment of eye disorders that cause blurred vision or a blind spot due to abnormal or blocked blood vessels.
- Trial name
- MAIA (NCT04137120)
- Testing
- Aflibercept (BAY86-5321, Eylea)
- Where
- Mexico
- Volunteers
- 73 people
- Sponsor
- Bayer
Vitreous Detachment, Diabetic Retinopathy
Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment
The purpose of this study is to assess the efficacy of intravitreous injections of Vitrase to induce posterior vitreous detachment(PVD) in subjects with moderate to severe non-proliferative diabetic retinopathy.
- Trial name
- NCT00198471
- Testing
- Vitrase
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Bausch & Lomb Incorporated
Macular Edema
Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)
To evaluate the efficacy of long-term treatment with 2 mg aflibercept via different intravitreal (IVT) treatment regimens to participants with DME pretreated with 2 mg aflibercept every 8 weeks after 5 initial monthly injections…
- Trial name
- VIOLET (NCT02818998)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- 64 sites in Austria, Canada and 12 more
- Volunteers
- 463 people
- Sponsor
- Bayer
Anesthesia, Local, Intravitreal Injection
Cooling Anesthesia for Intravitreal Injection
The purpose of this clinical study is to evaluate the safety and efficacy of cooling anesthesia application to the eye as anesthesia for intravitreal injection using a novel cooling anesthesia device and determine the effects of…
- Conditions
- Anesthesia, Local, Intravitreal Injection, Macular Degeneration, Diabetic Macular Edema
- Trial name
- COOL-1 (NCT03732287)
- Testing
- Cooling Anesthesia
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Recens Medical, Inc.
Diabetic Retinopathy, Diabetic Macular Edema
Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy
The objective of this study is to evaluate the safety and efficacy of APX3330 to treat diabetic retinopathy (DR) and diabetic macular edema (DME).
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema, NPDR - Non Proliferative Diabetic Retinopathy, PDR - Proliferative Diabetic Retinopathy
- Trial name
- ZETA-1 (NCT04692688)
- Testing
- APX3330
- Where
- 24 sites in United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Opus Genetics, Inc
Diabetes Mellitus, Type 2
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The study will be performed in people with type 2 diabetes.
- Trial name
- FOCUS (NCT03811561)
- Testing
- Semaglutide
- Where
- 230 sites in United States, Brazil and 17 more
- Volunteers
- 1,500 people
- Sponsor
- Novo Nordisk A/S
Normal Eyes, Age Related Macular Degeneration
High Resolution Imaging OCT Study
The goal of this pilot study is to compare image quality between the investigational devices (R1 and HighRes OCT) and the SPECTRALIS (cleared) in adult participants with normal and/or pathology eyes.
- Conditions
- Normal Eyes, Age Related Macular Degeneration, Diabetic Retinopathy, Eyes With Retinal Diseases
- Trial name
- NCT07338461
- Testing
- Autofluorescence Imaging, Infrared reflectance imaging, OCT imaging
- Where
- Italy
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Heidelberg Engineering GmbH
Retinopathy, Retinal Vein Occlusion
Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
The objective of this study is to evaluate the safety and image quality of the investigational dye, MB-102, compared to the control dye (fluorescein sodium) in healthy and diseased eyes using fluorescent angiography for retinal…
- Conditions
- Retinopathy, Retinal Vein Occlusion, Diabetic Retinopathy, Macular Degeneration
- Trial name
- NCT04008121
- Testing
- Fluorescein sodium and Zeiss FF450 fundus camera, MB-102 and Zeiss FF450 fundus camera, Fluorescein sodium and commercially available optical angiography imaging system
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- MediBeacon
Diabetic Retinopathy
Nesvategrast (OTT166) in Diabetic Retinopathy (DR)
This study will evaluate the safety and efficacy of OTT166 Ophthalmic solution in participants with Diabetic Retinopathy.
- Trial name
- NCT05409235
- Testing
- OTT166, Vehicle control
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 225 people
- Sponsor
- OcuTerra Therapeutics, Inc.
Diabetic Retinopathy
Multicenter Diagnostic Clinical Performance Study For Automated Detection of Diabetic Retinopathy
This study is a retrospective study to assess the efficacy and accuracy of the EyeCheckup software in screening for diabetic retinopathy in healthcare settings.
- Trial name
- NCT05471986
- Testing
- Color Fundus Photography/Non-Mydriatic Opthalmic Cameras
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Ural Telekomunikasyon Sanayi Ticaret Anonim Sirketi
Diabetic Retinopathy
A Multi-center Study to Evaluate Performance of an Automated Device for the Detection of Diabetic Retinopathy
Diabetes affects 30.3 million people or 9.3% of the population of the United States. Results of a study by the Eye Diseases Prevalence Research Group reveal that 40% of diabetes patients have some degree of diabetic retinopathy…
- Trial name
- NCT02963441
- Testing
- LumineticsCore (formerly IDX-DR)
- Volunteers
- 900 people
- Sponsor
- Digital Diagnostics, Inc.
Diabetic Macular Edema (DME)
Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-02)
This is a Phase 3 study of an investigational drug called OLN324, which is being developed by Ollin Biosciences as a treatment for patients with diabetic macular edema (DME).
- Trial name
- ATACAMA (NCT07841899)
- Testing
- OLN324, Aflibercept
- Volunteers
- 450 people
- Sponsor
- Ollin Biosciences, Inc.
Diabetic Macular Edema
A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME)
A multicenter study to compare multiple doses of intravitreal microplasmin for non-surgical PVD induction for treatment of patients with DME.
- Trial name
- MIVI-II (NCT00412451)
- Testing
- ocriplasmin
- Where
- 15 sites in Belgium, Germany and 4 more
- Volunteers
- 51 people
- Sponsor
- ThromboGenics
Diabetic Retinopathy
Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy
This multicenter, open-label extension study will evaluate the long-term tolerability and safety for patients completing study CSMS995 0802.
- Trial name
- NCT00248131
- Testing
- Octreotide acetate in microspheres
- Volunteers
- 260 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes, Diabetic Retinopathy
Diabetic Retinopathy Functional Evaluation Study: Monitoring Carotenoid Vitamins Treatment Using ERG
To evaluate the differences in retinal function as measured by ERG in diabetics with and without retinopathy 2) the ability of the Chromatic Electroretinogram (chERG) to detect changes in global retinal function following…
- Trial name
- NCT04117022
- Testing
- DVS supplementation
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- ZeaVision, LLC
Diabetic Retinopathy
A Study of PER-001 in Participants With Diabetic Retinopathy
This is a Phase 2a, randomized, single-masked (participant), sham controlled clinical study.
- Trial name
- NCT06003751
- Testing
- PER-001 Intravitreal Implant - Low Dose, PER-001 Intravitreal Implant - High Dose
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Perfuse Therapeutics, Inc.
Diabetes Mellitus, Diabetic Retinopathy
A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME)
This study is conducted to evaluate the safety of a single intravitreal injection of THR-149.
- Conditions
- Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
- Trial name
- NCT03511898
- Testing
- THR-149 dose level 1, THR-149 dose level 2, THR-149 dose level 3
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- ThromboGenics
Choroidal Neovascularization, Diabetic Retinopathy
PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
This is a two-part study. The first part (Stratum I) is an open-label, dose escalation, safety, tolerability and pharmacokinetic study, where active study drug (PF-04523655) will be given to all patients who participate.
- Conditions
- Choroidal Neovascularization, Diabetic Retinopathy, Diabetic Macular Edema
- Trial name
- MATISSE (NCT01445899)
- Testing
- PF-04523655 (Stratum I), ranibizumab, PF-04523655 (Stratum II)
- Where
- 51 sites in United States, Belgium and 5 more
- Volunteers
- 258 people
- Sponsor
- Quark Pharmaceuticals
Proliferative Diabetic Retinopathy (PDR)
Phase I Study Assessing the Ocular and Systemic Safety and Tolerability of OC-10X
The present study is intended to evaluate the safety and tolerability of topical OC-10X Ophthalmic Suspension in healthy human subjects. OcuCure Therapeutics, Inc.
- Trial name
- NCT01869933
- Testing
- OC-10X
- Where
- Bangladesh
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- OcuCure Therapeutics, Inc.